Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Colorcon
Dow
Merck
AstraZeneca

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2010)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2010)

Docket   Start Trial Date Filed 2010-06-04
Court District Court, D. New Jersey Date Terminated 2010-11-15
Cause 35:271 Patent Infringement Assigned To Mary Little Cooper
Jury Demand None Referred To Magistrate Judge Lois H. Goodm
Parties CADILA HEALTHCARE LTD.; OTSUKA PHARMACEUTICAL CO., LTD.; ZYDUS PHARMACEUTICALS USA, INC.
Patents 4,734,416; 5,006,528
Attorneys MELISSA ANNE CHUDEREWICZ; TRENT S. DICKEY; VINCENT R. LODATO
Firms Pepper Hamilton LLP
Link to Docket External link to docket
Small Molecule Drugs cited in OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-06-04 1 States Patent Number 5,006,528 ("the ’523 patent”), arising under the United States patent Iaws, … FOR PATENT INFRINGEMENT 9. The U.S. Patent and Trademark Of`fice (“PTO”) issued the ’528 patent, entitled…1991. A copy of the ’528 patent is attached as Exhibit A. lU. The ’528 patent is assigned to Otsuka. Otsuka…the ’528 patent as recorded by the PTO at Reel 014402, Frame 0284. ll. The PTO issued a Patent Term Extension…October 12, 2005. A copy of the Patent Terrn Extcnsion for the ’523 patent is attached as #12'.-' External link to document
2010-11-15 6 obviousness-type double patenting over Otsuka’s prior art U.S. Patent No. 4,734,416 (the “‘416 Patent”); and unenforceable…in the ‘416 Patent as well as Otsuka’s German Patent No. 2,912,105 (“the DE ‘105 Patent”); 2,3 dichloro… the ‘528 Patent as obvious over the disclosures in the ‘416 Patent and the DE ‘105 Patent of prior …a later patent that are not patentably distinct from claims in a commonly owned earlier patent.” Sun… the earlier patent and later patent are not part of the same patent family and issue from separate External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Boehringer Ingelheim
McKinsey
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.